Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935062 | 0.80 | PNP (0.70) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL15743133 | 0.79 | PNP (0.59) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6888654 | 0.78 | PI4KA (0.44) | TBXAS1 | |
| SCHEMBL8196747 | 0.77 | PNP (0.58) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6272728 | 0.77 | PNP (0.58) | PNPKDM4EMEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL17186401 | 0.76 | PNP (0.71) | PNPFGFR1FGFR2 | |
| SCHEMBL8522269 | 0.76 | PNP (0.56) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL21314870 | 0.76 | PNP (0.56) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL9806967 | 0.75 | PNP (0.63) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL7777164 | 0.75 | PNP (0.54) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045522-B2 | Nucleic acid amplification using a reversibly modified oligonucleotide | Bi, Wanli (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130122507-A1 | Nucleic Acid Amplification Using A Reversibly Modified Oligonucleotide | SUZHOU NUHIGH BIOTECHNOLOGIES CO., LTD (CN) | 2013-05-16 | — | — | US | disclosed |
| US-8334099-B2 | Nucleic acid amplification using a reversibly modified oligonucleotide | BI WANLI (US) | 2012-12-18 | — | — | US | disclosed |
| EP-2049689-B1 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010021897-A1 | NUCLEOSIDIC PHOSPHORAMIDITE CRYSTALLINE MATERIAL AND A PROCESS FOR PURIFYING THE SAME | MERCK SHARP & DOHME CORP. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100021970-A1 | Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide | BI WANLI | 2010-01-28 | — | — | US | disclosed |
| EP-2049689-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | Bi, Wanli (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016562-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2008-02-07 | — | — | WO | disclosed |
| US-7057062-B2 | Process for manufacturing purified phosphorodiamidite | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050026166-A1 | Concurrent enzymatic polynucleotide synthesis and detectable signal generation | NUSTAR LABORATORY | 2005-02-03 | — | — | US | disclosed |
| EP-1492800-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | IONIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087130-A2 | PROCESS FOR MANUFACTURING PURIFIED PHOSPHORODIAMIDITE | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225284-A1 | Process for manufacturing purified phosphorodiamidite | PHOSPHO1, PNP, OSGEP | PNP 2/4885KDM4E 3888/4885MEN1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.